These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19608483)

  • 1. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes.
    Ostojic M; Sagic D; Beleslin B; Jung R; Perisic Z; Jagic N; Nedeljkovic M; Mangovski L; Milosavljevic B; Stojkovic S; Orlic D; Antonic Z; Miloradovic V; Topic D; Paunovic D
    EuroIntervention; 2008 Mar; 3(5):574-9. PubMed ID: 19608483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
    Kadota K; Muramatsu T; Iwabuchi M; Saito S; Hayashi Y; Ikari Y; Nanto S; Fujii K; Inoue N; Namiki A; Kimura T; Mitsudo K
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):789-96. PubMed ID: 21805606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents.
    Jakobsen L; Christiansen EH; Maeng M; Hansen KN; Kristensen SD; Bøtker HE; Terkelsen CJ; Jensen SE; Raungaard B; Madsen M; Lassen JF; Jensen LO
    EuroIntervention; 2017 Dec; 13(11):1336-1344. PubMed ID: 28846543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.
    Nakamura M; Otsuka Y; Ueda Y; Mitsudo K
    Cardiovasc Interv Ther; 2012 Jan; 27(1):24-30. PubMed ID: 24122637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent.
    Pendyala LK; Matsumoto D; Shinke T; Iwasaki T; Sugimoto R; Hou D; Chen JP; Singh J; King SB; Chronos N; Li J
    JACC Cardiovasc Interv; 2012 Apr; 5(4):436-44. PubMed ID: 22516402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial.
    Chevalier B; Serruys PW; Silber S; Garcia E; Suryapranata H; Hauptmann K; Wijns W; Schuler G; Fath-Ordoubadi F; Worthley S; Thuesen L; Meredith I; Bressers M; Nagai H; Paunovic D
    EuroIntervention; 2007 Feb; 2(4):426-34. PubMed ID: 19755281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials.
    Cassese S; Fusaro M; Byrne RA; Tada T; Hoppmann P; Joner M; Laugwitz KL; Schunkert H; Kastrati A
    Int J Cardiol; 2014 Aug; 175(3):484-91. PubMed ID: 25012497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
    Windecker S; Serruys PW; Wandel S; Buszman P; Trznadel S; Linke A; Lenk K; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Davies S; van Geuns RJ; Eerdmans P; van Es GA; Meier B; Jüni P
    Lancet; 2008 Sep; 372(9644):1163-73. PubMed ID: 18765162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients.
    Otsuka Y; Saito S; Nakamura M; Shuto H; Mitsudo K
    Catheter Cardiovasc Interv; 2011 Dec; 78(7):1078-85. PubMed ID: 21538783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
    Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
    Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nobori biolimus-eluting stent vs. permanent polymer drug-eluting stents in patients undergoing percutaneous coronary intervention.
    Danzi GB; Piccolo R; Galasso G; Piscione F
    Circ J; 2014; 78(8):1858-66. PubMed ID: 24899233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.